Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BNC 105

Known as: BNC-105, BNC105 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
ABSTRACT Microtubule targeting agents, such as vinblastine, are usually thought to arrest cells in mitosis and subsequently… Expand
2014
2014
BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and… Expand
2012
2012
BNC105 is a small molecule that exerts anti-cancer activity through disruption of tubulin polymerization. BNC105 is unique in its… Expand
Highly Cited
2011
Highly Cited
2011
A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of… Expand
  • table 1
  • table 2
  • table 3
  • table 3
  • figure 2
2011
2011
Purpose: To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2010
Highly Cited
2010
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2010
Highly Cited
2010
A variety of approaches are available for generation of bacteria‐produced nanocellulose (BNC) in different forms. BNC production… Expand
2010
2010
Dow Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
2010
2010
3054 Background: BNC105P is a novel agent which inhibits tubulin polymerization and acts as a VDA. BNC105P is a phosphorylated… Expand
2009
2009
e14512 Background: BNC105P is a novel anticancer agent that inhibits tubulin polymerization and acts as a VDA. BNC105P is a… Expand